OncoMatch/Clinical Trials/NCT06456580
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Is NCT06456580 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Telitacicept for generalized myasthenia gravis.
Treatment: Telitacicept — The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CHRNA1 antibody positive
Patients have positive antibodies against AChR
Required: MUSK antibody positive
Patients have positive antibodies against MuSK
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California · Los Angeles, California
- University of California Irvine · Orange, California
- University of California San Francisco (UCSF) · San Francisco, California
- SFM Clinical Research · Boca Raton, Florida
- Allied Biomedical Research Institute (ABRI) · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06456580 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CHRNA1?
Yes, CHRNA1 antibody positive is a required biomarker for enrollment.
Does this trial require MUSK?
Yes, MUSK antibody positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify